Hologic Taking Action with 'Hey, U!' Campaign
to Educate Women in Conjunction with Fibroid Awareness Month
A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a
global leader in women’s health, revealed a lack of awareness among
U.S. women about uterine health, including uterine fibroid symptoms
and treatment options. Today, in conjunction with the start of
Fibroid Awareness Month, Hologic is proud to announce the launch of
Hey, U!, an educational campaign focused on uterine health.
Uterine fibroids are very common, affecting up to 80% of women
by the age of 50.1 Even so, Hologic's survey found that 48% of U.S.
women are unaware that a hysterectomy is not the only way to treat
uterine fibroids.2 Additionally, the survey revealed that just over
half of U.S. women (51%) are unaware that uterine fibroids are not
a form of cancer.2
"These survey results confirm that despite the significant
number of women impacted by uterine fibroids, there remain many who
are unaware of the treatment options available to them," said Essex
Mitchell, Hologic’s Division President, Surgical. "There is a
sizeable knowledge gap when it comes to overall uterine health,
including symptoms and treatment options for common issues like
uterine fibroids."
Additional survey highlights2 include:
- Less than half of U.S. women (49%) are aware that uterine
fibroids do not always cause painful symptoms
- Less than half of U.S. women (47%) are aware that uterine
fibroids do not always cause infertility
- Less than half of U.S. women (48%) are confident they could
identify the five major parts of the uterus
- Less than half of U.S. women (47%) are confident they could
identify the difference between fibroids, polyps and cysts
The survey also sheds light on experiences with heavy menstrual
bleeding and its impact on daily life, as roughly two thirds of
U.S. women (66%) say their menstrual period has impacted their
day-to-day life, and nearly half (49%) say they have leaked through
their clothing. 2 Additionally, nearly a third of U.S. women
reported being embarrassed to discuss their menstrual bleeding or
pain with others.2 Given that many symptoms of uterine fibroids can
be confused for common menstrual period issues, it's imperative
that women feel comfortable talking about these issues with their
healthcare providers.
Mitchell continued, “As a global leader in women's health, we
are committed to providing physicians and their patients with
resources to help identify and treat the symptoms of uterine
fibroids, which are a serious problem for a large majority of
women. Our Hey, U! campaign is a great example of our commitment in
action, and we're proud to launch it today, at the start of Fibroid
Awareness Month."
The campaign features a dynamic digital destination, KnowYourU,
where women and clinicians can access a comprehensive library of
tools and resources on everything from overall uterine health to
more specific fibroid-focused content. The focal point of the
landing page is a series of animated short videos explaining the
basics of uterine health, fibroid symptoms and potential solutions
through accessible language and colorful visuals. Additional
content includes a patient symptom quiz, downloadable discussion
guides and information on various fibroid treatment solutions. To
amplify these resources, Hologic is partnering with lifestyle and
clinician influencers, as well as developing a toolkit for
healthcare provider use during Fibroid Awareness Month and
beyond.
Historically, a hysterectomy was the traditional treatment for
uterine fibroids. While it remains a viable and sometimes necessary
procedure for some women suffering from fibroids, Hologic now
offers minimally invasive treatment options as an alternative to
major surgery and hysterectomy. Those options include the Acessa®
laparoscopic radiofrequency ablation system for the treatment of
fibroids and the MyoSure® tissue removal system for the removal of
intrauterine fibroids and polyps. For times when a hysterectomy is
determined to be the best option by a healthcare provider, Hologic
offers additional tools with the CoolSeal® vessel sealing
portfolio, designed to improve both patient and clinician
experience in open and laparoscopic procedures.
Learn more at GynSurgicalSolutions.com.
Survey Method:
This survey was conducted online within the United States by The
Harris Poll on behalf of Hologic from May 10-12, 2022 among 997
female U.S. adults ages 18 and older. The sampling precision of
Harris online polls is measured by using a Bayesian credible
interval. For this study, the sample data is accurate to within
+2.8 percentage points using a 95% confidence level. For complete
survey methodology, including weighting variables and subgroup
sample sizes, please contact Bridget Perry at
bridget.perry@hologic.com.
About Hologic, Inc.
Hologic, Inc. is a medical technology innovator primarily
focused on improving women’s health and well-being through early
detection and treatment. Its advancements include invention of 3D
mammography to fight breast cancer; leadership in testing for
cervical cancer, sexually transmitted infections, respiratory
illnesses and the virus that causes COVID-19; and minimally
invasive surgical technologies for uterine fibroids and abnormal
uterine bleeding. The Company also champions women through the
Hologic Global Women’s Health Index, which provides a
science-backed data roadmap for improving women’s well-being, and
Project Health Equality, which elevates awareness, research
insights and access to quality care for underserved women. For more
information on Hologic, visit www.hologic.com.
Hologic, Acessa, CoolSeal, MyoSure, The Science of Sure and
associated logos are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or
other countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Source: Hologic, Inc.
_____________________________________
1 Uterine Fibroid Fact Sheet. Office on Women’s Health. U.S.
Department of Health & Human Services.
https://www.womenshealth.gov/a-z-topics/uterine-fibroids. Accessed
February 20, 2019.
2 This survey was conducted online within the United States by
The Harris Poll on behalf of Hologic between May 10-12, 2022 among
997 female adults ages 18+.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220701005024/en/
Media Contact: Jane Mazur Vice President, Corporate
Communications 508.263.8764 jane.mazur@hologic.com
Investor Contact: Ryan Simon Vice President, Investor
Relations 858.410.8514 ryan.simon@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Apr 2023 to Apr 2024